Prostate Cancer Prevention
Prostate Cancer Prevention
Prostate cancer cannot be prevented by any known means, and no diet, supplement or lifestyle change has been shown to stop it developing. What can be done well is detection: deciding deliberately whether and when to test with PSA, understanding what a positive result leads to, and starting earlier for men whose family history or genes put them at higher risk.
What PSA screening does — and costs
Prostate cancer is the one common cancer where screening is a genuine argument rather than a settled recommendation, and the reason is structural: the test finds a great deal of disease that would never have harmed anyone. Large trials of PSA screening have shown a reduction in deaths from prostate cancer, at the cost of diagnosing many men whose tumours would have remained silent for the rest of their lives — and diagnosing them leads to biopsies, anxiety and, historically, to treatment they did not need.
The overdiagnosis problem is not a flaw in the test so much as a consequence of the disease's natural history. A substantial proportion of older men carry small, low-grade tumours that never progress, and a blood test cannot distinguish those from the ones that will. That is why the modern pathway adds MRI before biopsy — reducing unnecessary biopsies — and why active surveillance exists as an exit for the men whose low-risk disease is found.
The balance has therefore shifted from whether to screen at all toward how to screen well: test with a clear understanding of what a raised result leads to, use MRI to decide who needs a biopsy, and treat low-risk findings by monitoring rather than by intervening. That sequence is what turns an ambiguous test into a usable one.
How the decision should be made
Because the trade-off is real in both directions, guidelines recommend a shared decision between a man and his clinician rather than routine testing for everyone or testing for no one. The conversation should cover four things:
- What the test can find — early disease that may benefit from treatment, and also low-risk tumours that may never need it.
- What follows a raised result — usually a repeat PSA, then multiparametric MRI, then biopsy only where the MRI or the trend justifies it. The pathway matters more than the number.
- What follows a diagnosis — for low-risk findings, active surveillance is frequently the appropriate route rather than immediate treatment; for higher-risk findings, treatment decisions about surgery and radiotherapy follow.
- The man's own priorities — how he weighs the possibility of early detection against the possibility of being diagnosed with something that would never have troubled him.
A second practical element is the baseline value. A single PSA measurement is far less informative than a baseline taken in a man's forties or early fifties and followed over time, because it is the trend that distinguishes a slowly enlarging benign gland from something developing. Whatever is decided about subsequent testing, having a documented baseline makes every later decision easier.
Starting earlier when risk is higher
For a minority of men, the balance of the screening discussion tilts clearly toward earlier and more structured testing, because their risk is concentrated rather than average:
- A father or brother with prostate cancer, particularly if diagnosed before 60 — the usual advice is to begin the discussion earlier than the standard age.
- A known BRCA2 variant — associated with a higher risk and a more aggressive disease course; carriers warrant a defined surveillance plan, and the variant also changes treatment options if cancer develops.
- Lynch syndrome — raises prostate cancer risk alongside the better-known colon and endometrial risks, and belongs in the same surveillance plan.
- African ancestry — higher incidence and earlier onset, which justifies beginning the conversation sooner rather than at the general recommended age.
For these men, genetic counselling is worth arranging, because the answer may extend beyond the patient: if a germline variant is identified, brothers and sons can be tested, and those who carry it gain a plan rather than a vague sense of unease. That is the difference between early detection as a general policy and early detection as a targeted programme.
Weight, smoking and activity
Lifestyle does not prevent this cancer, but it influences how it behaves and how treatment is tolerated, which is a different and more defensible claim:
- Not smoking — associated with a lower risk of dying from prostate cancer and with less aggressive disease.
- Maintaining a healthy weight — obesity is linked to more aggressive tumours and to a higher risk of recurrence after treatment.
- Resistance and aerobic exercise — matters most for men on hormone therapy, where it protects muscle mass, bone density and cardiovascular health, and demonstrably improves how treatment is tolerated.
- Avoiding supplements marketed for prostate health — selenium and vitamin E failed to show benefit in large trials, and one trial suggested harm.
Framed honestly, none of these is a prevention strategy — they are risk-modification measures with the clearest evidence in men who already have a diagnosis or are on treatment. For a man without a diagnosis, the more consequential action is not a diet change but the decision about whether and when to test.
What prevention cannot do
An honest page states its limits. There is no way to prevent prostate cancer: no diet, no supplement, no lifestyle measure, and no surgery such as prophylactic removal of the gland in the way that risk-reducing surgery exists for some other hereditary cancers. The two dominant risk factors — age and inherited genetics — cannot be changed.
Screening likewise cannot be presented as prevention. It changes when a cancer is found, not whether it occurs, and it carries its own costs: false alarms, biopsies that turn out negative, anxiety, and the diagnosis of tumours that would never have caused harm. What screening genuinely offers is a chance to find significant disease earlier — and for a man at average risk, whether that chance is worth those costs is a judgement he is entitled to make, which is precisely why the decision is shared rather than imposed.
The version of this page that would be dishonest is one promising avoidance. The version that is useful says: the disease may be unavoidable, the detection can be done thoughtfully, and for higher-risk men earlier testing is a genuine advantage.
A practical plan
Condensed to what a reader can act on:
- At average risk — discuss PSA testing with a clinician once, properly: what the test finds, what follows a raised result, and whether the trend over time would be informative. Get a documented baseline when the discussion happens, because it makes later decisions easier.
- If a father or brother had prostate cancer, or if you are of African ancestry — begin that discussion earlier rather than at the general recommended age.
- If BRCA2, Lynch syndrome, or several relatives with prostate, breast, ovarian or pancreatic cancer are in the family — ask for genetic counselling and testing; the result changes surveillance for you and for your relatives.
- If a raised PSA is found — expect a repeat test, then multiparametric MRI, and biopsy only where the MRI or the trend warrants it; ask for the PI-RADS score and, if a biopsy is done, the grade group.
For readers weighing what happens after a diagnosis rather than before one, the treatment page sets out how risk category decides between surveillance, surgery and radiotherapy.